RTW Investments, LP and its Managing Partner Roderick Wong, M.D. filed Amendment No. 4 to their beneficial ownership statement covering Tenax Therapeutics, Inc. common stock, disclosing a position of zero shares as of September 30, 2026, with the filing submitted on November 16, 2026.
Rafael Holdings, Inc. filed a definitive proxy statement on November 16, 2026, soliciting stockholder votes for its 2027 Annual Meeting of Stockholders scheduled for January 7, 2027, at the company's offices in Newark, New Jersey.
RTW Investments, LP and Roderick Wong filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 103,509,730 ordinary shares of Zai Lab Limited as of September 30, 2026.
AQR Capital Management, LLC, AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC jointly filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of Class A ordinary shares in AMR Resources Acquisition Corp. as of September 30, 2026.
Accelevation Holdings Corp. filed a Form 8-K/A on November 16, 2026, amending its November 12, 2026 current report to correct two errors in the press release covering financial results for the quarter ended September 30, 2026.
Our Bond, Inc. filed a Form 8-K on November 16, 2026, disclosing that its Board of Directors approved on November 15, 2026, the conversion of Series B Preferred Stock with a total stated value of $13,261,259.92 into 6,532,640 shares of common stock at a …
Corbus Pharmaceuticals Holdings, Inc. filed a Form 8-K on November 16, 2026, disclosing additional Phase 1b clinical trial data for CRB-913 in obesity that were presented in a poster at ObesityWeek 2026 in Washington, D.C.
DeFi Development Corp. filed a Form 8-K with the SEC on November 16, 2026, disclosing that its SOL and SOL Equivalents grew by 9,482 during the period from November 9, 2026 through November 13, 2026.
Corvex, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing that it entered into a definitive three-year, $103 million take-or-pay agreement to provide NVIDIA Blackwell computing capacity to a scaled AI inference platform.
Akebia Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that on November 12, 2026, the company entered into a senior secured term loan facility of up to $140.0 million with Symbiotic Capital Opportunities Holding, L.P. as lender and Symbiotic Capital Agency …